Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

1.

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. doi: 10.1073/pnas.1215397109. Epub 2012 Oct 8.

PMID:
23045683
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.

J Clin Oncol. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725. Epub 2012 Jun 11.

PMID:
22689807
[PubMed - indexed for MEDLINE]
3.

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM.

Clin Cancer Res. 2012 Jun 15;18(12):3478-86. doi: 10.1158/1078-0432.CCR-11-2294. Epub 2012 Apr 13.

PMID:
22504044
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P.

J Clin Oncol. 2012 Jun 1;30(16):1989-95. doi: 10.1200/JCO.2011.39.0823. Epub 2012 Apr 9.

PMID:
22493419
[PubMed - indexed for MEDLINE]
5.

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.

Martín M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, Scotto N, Mitchell L, Tjulandin S.

Oncologist. 2012;17(4):469-75. doi: 10.1634/theoncologist.2011-0344. Epub 2012 Mar 30.

PMID:
22467666
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA.

Clin Cancer Res. 2011 Jul 15;17(14):4834-43. doi: 10.1158/1078-0432.CCR-10-2962.

PMID:
21768129
[PubMed - indexed for MEDLINE]
Free Article
7.

Molecular mechanisms and clinical applications of angiogenesis.

Carmeliet P, Jain RK.

Nature. 2011 May 19;473(7347):298-307. doi: 10.1038/nature10144. Review.

PMID:
21593862
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The biology of brain metastases-translation to new therapies.

Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK.

Nat Rev Clin Oncol. 2011 Jun;8(6):344-56. doi: 10.1038/nrclinonc.2011.58. Epub 2011 Apr 12. Review.

PMID:
21487419
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

HER2011: the changing face of HER2-positive breast cancer.

Sledge GW Jr.

Clin Breast Cancer. 2011 Mar;11(1):9. doi: 10.3816/CBC.2011.n.001. No abstract available.

PMID:
21421515
[PubMed - indexed for MEDLINE]
10.

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.

Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6. doi: 10.1073/pnas.1016140108. Epub 2011 Mar 8.

PMID:
21385943
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The role of the organ microenvironment in brain metastasis.

Fidler IJ.

Semin Cancer Biol. 2011 Apr;21(2):107-12. doi: 10.1016/j.semcancer.2010.12.009. Epub 2010 Dec 16. Review.

PMID:
21167939
[PubMed - indexed for MEDLINE]
12.

Preclinical approaches to study the biology and treatment of brain metastases.

Cruz-Muñoz W, Kerbel RS.

Semin Cancer Biol. 2011 Apr;21(2):123-30. doi: 10.1016/j.semcancer.2010.12.001. Epub 2010 Dec 13. Review.

PMID:
21147227
[PubMed - indexed for MEDLINE]
13.

Bevacizumab safety in patients with central nervous system metastases.

Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP.

Clin Cancer Res. 2010 Jan 1;16(1):269-78. doi: 10.1158/1078-0432.CCR-09-2439. Epub 2009 Dec 22.

PMID:
20028762
[PubMed - indexed for MEDLINE]
Free Article
14.

Real-time imaging reveals the single steps of brain metastasis formation.

Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F.

Nat Med. 2010 Jan;16(1):116-22. doi: 10.1038/nm.2072. Epub 2009 Dec 20.

PMID:
20023634
[PubMed - indexed for MEDLINE]
15.

Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases.

Chung E, Yamashita H, Au P, Tannous BA, Fukumura D, Jain RK.

PLoS One. 2009 Dec 15;4(12):e8316. doi: 10.1371/journal.pone.0008316.

PMID:
20016816
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
[PubMed - indexed for MEDLINE]
17.

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.

Leyland-Jones B.

J Clin Oncol. 2009 Nov 1;27(31):5278-86. doi: 10.1200/JCO.2008.19.8481. Epub 2009 Sep 21. Review.

PMID:
19770385
[PubMed - indexed for MEDLINE]
18.

Genes that mediate breast cancer metastasis to the brain.

Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J.

Nature. 2009 Jun 18;459(7249):1005-9. doi: 10.1038/nature08021. Epub 2009 May 6.

PMID:
19421193
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP.

Clin Cancer Res. 2009 Feb 15;15(4):1452-9. doi: 10.1158/1078-0432.CCR-08-1080.

PMID:
19228746
[PubMed - indexed for MEDLINE]
Free Article
20.

Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.

Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC Jr.

Cell Cycle. 2008 Dec;7(23):3747-58. Epub 2008 Dec 16.

PMID:
19029832
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk